Physician profile
John G Flores
NPI 1568449593
$110,590.60
in general payments reported to CMS, 2019-2025
30 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $37K · 2021: $35K · 2022: $26K · 2023: $8,208 · 2024: $1,430 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,148 · Food and Beverage: $4,529 · Travel and Lodging: $1,481 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,147.50 |
| Food and Beverage | $4,529.28 |
| Travel and Lodging | $1,481.48 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103,577.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,162.40 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Abbott Laboratories | $1,017.89 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $668.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $398.09 | 2019-2021 | |
| Eisai INC. | $336.77 | 2020-2022 | |
| Corcept Therapeutics | $327.05 | 2024-2025 | Korlym |
| Dexcom, INC. | $308.44 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbvie INC. | $272.89 | 2022-2025 | |
| Amgen INC. | $194.55 | 2023-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $184.44 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $161.12 | 2019-2023 | Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $152.47 | 2021-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $146.30 | 2023 | Inpefa |
| Amarin Pharma, INC. | $129.26 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $76.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $71.87 | 2020 | |
| Kvk-Tech, INC. | $52.31 | 2021 | |
| Avvisto Therapeutics, LLC | $49.86 | 2024-2025 | Cycloset |
| Novartis Pharmaceuticals Corporation | $46.46 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $43.56 | 2025 | Recorlev, Gvoke Hypopen |
| Pfizer INC. | $40.97 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $31.81 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $26.42 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.68 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.82 | 2019 | |
| Lundbeck LLC | $18.82 | 2025 | Vyepti |
| Idorsia Pharmaceuticals US INC | $18.69 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.50 | 2025 | Xifaxan |
| Currax Pharmaceuticals LLC | $15.86 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.